988 related articles for article (PubMed ID: 33154106)
21. Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia.
Asarnow D; Wang B; Lee WH; Hu Y; Huang CW; Faust B; Ng PML; Ngoh EZX; Bohn M; Bulkley D; Pizzorno A; Ary B; Tan HC; Lee CY; Minhat RA; Terrier O; Soh MK; Teo FJ; Yeap YYC; Seah SGK; Chan CEZ; Connelly E; Young NJ; Maurer-Stroh S; Renia L; Hanson BJ; Rosa-Calatrava M; Manglik A; Cheng Y; Craik CS; Wang CI
Cell; 2021 Jun; 184(12):3192-3204.e16. PubMed ID: 33974910
[TBL] [Abstract][Full Text] [Related]
22. A high-affinity RBD-targeting nanobody improves fusion partner's potency against SARS-CoV-2.
Yao H; Cai H; Li T; Zhou B; Qin W; Lavillette D; Li D
PLoS Pathog; 2021 Mar; 17(3):e1009328. PubMed ID: 33657135
[TBL] [Abstract][Full Text] [Related]
23. Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies.
Zhu X; Mannar D; Srivastava SS; Berezuk AM; Demers JP; Saville JW; Leopold K; Li W; Dimitrov DS; Tuttle KS; Zhou S; Chittori S; Subramaniam S
PLoS Biol; 2021 Apr; 19(4):e3001237. PubMed ID: 33914735
[TBL] [Abstract][Full Text] [Related]
24. Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody.
Yin W; Xu Y; Xu P; Cao X; Wu C; Gu C; He X; Wang X; Huang S; Yuan Q; Wu K; Hu W; Huang Z; Liu J; Wang Z; Jia F; Xia K; Liu P; Wang X; Song B; Zheng J; Jiang H; Cheng X; Jiang Y; Deng SJ; Xu HE
Science; 2022 Mar; 375(6584):1048-1053. PubMed ID: 35133176
[TBL] [Abstract][Full Text] [Related]
25. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2.
Shi R; Shan C; Duan X; Chen Z; Liu P; Song J; Song T; Bi X; Han C; Wu L; Gao G; Hu X; Zhang Y; Tong Z; Huang W; Liu WJ; Wu G; Zhang B; Wang L; Qi J; Feng H; Wang FS; Wang Q; Gao GF; Yuan Z; Yan J
Nature; 2020 Aug; 584(7819):120-124. PubMed ID: 32454512
[TBL] [Abstract][Full Text] [Related]
26. The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization.
Zebardast A; Hosseini P; Hasanzadeh A; Latifi T
Mol Biol Rep; 2022 Jan; 49(1):647-656. PubMed ID: 34648139
[TBL] [Abstract][Full Text] [Related]
27. Correlation between the binding affinity and the conformational entropy of nanobody SARS-CoV-2 spike protein complexes.
Mikolajek H; Weckener M; Brotzakis ZF; Huo J; Dalietou EV; Le Bas A; Sormanni P; Harrison PJ; Ward PN; Truong S; Moynie L; Clare DK; Dumoux M; Dormon J; Norman C; Hussain N; Vogirala V; Owens RJ; Vendruscolo M; Naismith JH
Proc Natl Acad Sci U S A; 2022 Aug; 119(31):e2205412119. PubMed ID: 35858383
[TBL] [Abstract][Full Text] [Related]
28. Structural Biology of Nanobodies against the Spike Protein of SARS-CoV-2.
Tang Q; Owens RJ; Naismith JH
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835020
[TBL] [Abstract][Full Text] [Related]
29. A non-ACE2-blocking neutralizing antibody against Omicron-included SARS-CoV-2 variants.
Duan X; Shi R; Liu P; Huang Q; Wang F; Chen X; Feng H; Huang W; Xiao J; Yan J
Signal Transduct Target Ther; 2022 Jan; 7(1):23. PubMed ID: 35078968
[No Abstract] [Full Text] [Related]
30. Allosteric Determinants of the SARS-CoV-2 Spike Protein Binding with Nanobodies: Examining Mechanisms of Mutational Escape and Sensitivity of the Omicron Variant.
Verkhivker G
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216287
[TBL] [Abstract][Full Text] [Related]
31. Enhanced potency of an IgM-like nanobody targeting conserved epitope in SARS-CoV-2 spike N-terminal domain.
Liu B; Liu H; Han P; Wang X; Wang C; Yan X; Lei W; Xu K; Zhou J; Qi J; Fan R; Wu G; Tian WX; Gao GF; Wang Q
Signal Transduct Target Ther; 2024 May; 9(1):131. PubMed ID: 38740785
[TBL] [Abstract][Full Text] [Related]
32. An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants.
Chi X; Zhang X; Pan S; Yu Y; Shi Y; Lin T; Duan H; Liu X; Chen W; Yang X; Chen L; Dong X; Ren L; Ding Q; Wang J; Yang W
Signal Transduct Target Ther; 2022 Feb; 7(1):44. PubMed ID: 35140196
[TBL] [Abstract][Full Text] [Related]
33. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
[TBL] [Abstract][Full Text] [Related]
34. Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein.
Lu Q; Zhang Z; Li H; Zhong K; Zhao Q; Wang Z; Wu Z; Yang D; Sun S; Yang N; Zheng M; Chen Q; Long C; Guo W; Yang H; Nie C; Tong A
J Nanobiotechnology; 2021 Jan; 19(1):33. PubMed ID: 33514385
[TBL] [Abstract][Full Text] [Related]
35. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
[TBL] [Abstract][Full Text] [Related]
36. Single domain shark VNAR antibodies neutralize SARS-CoV-2 infection in vitro.
Gauhar A; Privezentzev CV; Demydchuk M; Gerlza T; Rieger J; Kungl AJ; Walsh FS; Rutkowski JL; Stocki P
FASEB J; 2021 Nov; 35(11):e21970. PubMed ID: 34637549
[TBL] [Abstract][Full Text] [Related]
37. A broad neutralizing nanobody against SARS-CoV-2 engineered from an approved drug.
Liu Q; Lu Y; Cai C; Huang Y; Zhou L; Guan Y; Fu S; Lin Y; Yan H; Zhang Z; Li X; Yang X; Yang H; Guo H; Lan K; Chen Y; Hou SC; Xiong Y
Cell Death Dis; 2024 Jun; 15(6):458. PubMed ID: 38937437
[TBL] [Abstract][Full Text] [Related]
38. Structure-guided design of a trivalent nanobody cluster targeting SARS-CoV-2 spike protein.
Jiang X; Qin Q; Zhu H; Qian J; Huang Q
Int J Biol Macromol; 2024 Jan; 256(Pt 1):128191. PubMed ID: 38000614
[TBL] [Abstract][Full Text] [Related]
39. The ACE2-binding Interface of SARS-CoV-2 Spike Inherently Deflects Immune Recognition.
Hattori T; Koide A; Noval MG; Panchenko T; Romero LA; Teng KW; Tada T; Landau NR; Stapleford KA; Koide S
J Mol Biol; 2021 Feb; 433(3):166748. PubMed ID: 33310017
[TBL] [Abstract][Full Text] [Related]
40. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.
Liu L; Wang P; Nair MS; Yu J; Rapp M; Wang Q; Luo Y; Chan JF; Sahi V; Figueroa A; Guo XV; Cerutti G; Bimela J; Gorman J; Zhou T; Chen Z; Yuen KY; Kwong PD; Sodroski JG; Yin MT; Sheng Z; Huang Y; Shapiro L; Ho DD
Nature; 2020 Aug; 584(7821):450-456. PubMed ID: 32698192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
